IADR Abstract Archives
Immunotherapy of HIV Related Malignancies
Objectives: We review current fundamental concepts regarding different immunotherapies used for the treatment of malignancies related to HIV
Methods: A literature review was carried out through MEDLINE database using its interface PubMed with appropriate keywords and criteria.
Results: Cancer has become a major cause of death and morbidity in PLWH. Incidence of ADCs has declined in favor of NADCs such as anal cancer, Hodgkin lymphoma melanoma, lung cancer and head and neck cancer. Today, ART helps in preserving the immune function and limits infectious complications, therefore exclusion from clinical trial based on HIV infection is no longer adequate. Some recommendations have been provided by HIV Working Group for the enrolment of patients with HIV in clinical trials . The programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors are among the most effective novel cancer treatment agents that have gained widespread use of immunotherapies in the last decade. They have changed the treatment paradigm for many cancers, including non-small cell lung cancer (NSCLC) melanoma, and Hodgkin lymphoma CAR T-cell therapy is a cancer treatment that uses a patient’s own immune system cells, called T cells. These cells are modified to better recognize and kill the patient’s cancer. The T cells are engineered in the laboratory and then infused back into the patient.
Conclusions: As the population of PLWH ages due to advances in ART. Literature on cancer care of PLWH suggest that oncologists are asked to offer new therapies for cancer treatments.
Methods: A literature review was carried out through MEDLINE database using its interface PubMed with appropriate keywords and criteria.
Results: Cancer has become a major cause of death and morbidity in PLWH. Incidence of ADCs has declined in favor of NADCs such as anal cancer, Hodgkin lymphoma melanoma, lung cancer and head and neck cancer. Today, ART helps in preserving the immune function and limits infectious complications, therefore exclusion from clinical trial based on HIV infection is no longer adequate. Some recommendations have been provided by HIV Working Group for the enrolment of patients with HIV in clinical trials . The programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors are among the most effective novel cancer treatment agents that have gained widespread use of immunotherapies in the last decade. They have changed the treatment paradigm for many cancers, including non-small cell lung cancer (NSCLC) melanoma, and Hodgkin lymphoma CAR T-cell therapy is a cancer treatment that uses a patient’s own immune system cells, called T cells. These cells are modified to better recognize and kill the patient’s cancer. The T cells are engineered in the laboratory and then infused back into the patient.
Conclusions: As the population of PLWH ages due to advances in ART. Literature on cancer care of PLWH suggest that oncologists are asked to offer new therapies for cancer treatments.